Advisory Commission on Childhood Vaccines; Notice of Meeting, 9235-9236 [2014-03441]

Download as PDF 9235 Federal Register / Vol. 79, No. 32 / Tuesday, February 18, 2014 / Notices Dated: February 6, 2014. Leslie Kux, Assistant Commissioner for Policy. [FR Doc. 2014–03353 Filed 2–14–14; 8:45 am] BILLING CODE 4160–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Health Resources and Services Administration Agency Information Collection Activities: Proposed Collection: Public Comment Request Health Resources and Services Administration, HHS. ACTION: Notice. AGENCY: In compliance with the requirement for opportunity for public comment on proposed data collection projects (Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995), the Health Resources and Services Administration (HRSA) announces plans to submit an Information Collection Request (ICR), described below, to the Office of Management and Budget (OMB). Prior to submitting the ICR to OMB, HRSA seeks comments from the public regarding the burden estimate, below, or any other aspect of the ICR. DATES: Comments on this Information Collection Request must be received within 60 days of this notice. ADDRESSES: Submit your comments to paperwork@hrsa.gov or mail the HRSA Information Collection Clearance Officer, Room 10–29, Parklawn Building, 5600 Fishers Lane, Rockville, MD 20857. FOR FURTHER INFORMATION CONTACT: To request more information on the SUMMARY: proposed project or to obtain a copy of the data collection plans and draft instruments, email paperwork@hrsa.gov or call the HRSA Information Collection Clearance Officer at (301) 443–1984. SUPPLEMENTARY INFORMATION: When submitting comments or requesting information, please include the information request collection title for reference. Information Collection Request Title: Rural Health Care Services Outreach Supplement Performance Measures. OMB No. 0915–xxxx—NEW Abstract: The fiscal year (FY) 2013 supplemental funding to the Rural Health Care Services Outreach Program grantees is a one-time supplemental funding under Section 330A(e) of the Public Health Service (PHS) Act (42 U.S.C. 254c(e)) to promote rural health care services outreach by expanding the delivery of health care services to include new and enhanced services in rural areas. The supplemental funding will specifically focus on supporting the current scope of their project, allowing grantees to further enhance outreach and enrollment assistance activities in their communities. This supplemental funding will support the Affordable Care Act’s (ACA) outreach and enrollment activities to the Health Insurance Marketplaces. Grantees will be able to raise awareness of affordable insurance options and provide assistance and information to the uninsured about enrolling in available sources of insurance, such as Medicare, Medicaid, the Children’s Health Insurance Program (CHIP), and private insurance in the Marketplace through this supplemental funding. The overarching goal is to increase the number of eligible individuals educated about their coverage options and Number of responses per respondent Number of respondents Form name enrollees to the Health Insurance Marketplaces or other available sources of insurance, such as Medicare, Medicaid, and the Children’s Health Insurance Program as a result of this supplemental funding. Need and Proposed Use of the Information: For this program, performance measures were drafted to provide data to the program and to enable HRSA to provide aggregate program data. These measures cover the principal topic areas of interest to the Office of Rural Health Policy, including: (a) Organizational information; (b) outreach and enrollment personnel; (c) outreach and education; (d) enrollment; and (e) additional resources. Several measures will be used for this program. Likely Respondents: The respondents would be recipients of the Rural Health Care Services Outreach supplemental funding award. Burden Statement: Burden in this context means the time expended by persons to generate, maintain, retain, disclose or provide the information requested. This includes the time needed to review instructions; to develop, acquire, install and utilize technology and systems for the purpose of collecting, validating and verifying information, processing and maintaining information, and disclosing and providing information; to train personnel and to be able to respond to a collection of information; to search data sources; to complete and review the collection of information; and to transmit or otherwise disclose the information. The total annual burden hours estimated for this Information Collection Request are summarized in the table below. Total Estimated Annualized burden hours: Total responses Average burden per response (in hours) Total burden hours 52 1 52 1.5 78 Total ................................................ tkelley on DSK3SPTVN1PROD with NOTICES Rural Health Care Services Outreach Supplement Performance Measures .. 52 1 52 1.5 78 HRSA specifically requests comments on (1) the necessity and utility of the proposed information collection for the proper performance of the agency’s functions; (2) the accuracy of the estimated burden; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) the use of automated collection techniques or other forms of information VerDate Mar<15>2010 20:58 Feb 14, 2014 Jkt 232001 technology to minimize the information collection burden. Dated: February 10, 2014. Jackie Painter, Deputy Director, Division of Policy and Information Coordination. [FR Doc. 2014–03442 Filed 2–14–14; 8:45 am] DEPARTMENT OF HEALTH AND HUMAN SERVICES Health Resources and Services Administration Advisory Commission on Childhood Vaccines; Notice of Meeting BILLING CODE 4165–15–P PO 00000 In accordance with section 10(a)(2) of the Federal Advisory Committee Act Frm 00079 Fmt 4703 Sfmt 4703 E:\FR\FM\18FEN1.SGM 18FEN1 tkelley on DSK3SPTVN1PROD with NOTICES 9236 Federal Register / Vol. 79, No. 32 / Tuesday, February 18, 2014 / Notices (Public Law 92–463), notice is hereby given of the following meeting: Name: Advisory Commission on Childhood Vaccines (ACCV). Date and Time: March 6, 2014, 1:00 p.m. to 4:15 p.m. EDT; March 7, 2014, 9:00 a.m. to 12:00 p.m. EDT. Place: Parklawn Building (and via audio conference call and Adobe Connect), Conference Room 10–65, 5600 Fishers Lane, Rockville, MD 20857. The ACCV will meet on Thursday, March 6, 2014, 1:00 p.m. to 4:15 p.m. EDT and Friday, March 7, 2014, 9:00 a.m. to 12:00 p.m. EDT. The public can join the meeting by: 1. (In Person) Persons interested in attending the meeting [in person] are encouraged to submit a written notification to: Annie Herzog, DVIC, Healthcare Systems Bureau (HSB), Health Resources and Services Administration (HRSA), Room 11C–26, 5600 Fishers Lane, Rockville, Maryland 20857 or email: aherzog@hrsa.gov. Since this meeting is held in a federal government building, attendees will need to go through a security check to enter the building and participate in the meeting. This written notification is encouraged so that a list of attendees can be provided to expedite entry through security. Persons may attend in person without providing written notification, but their entry into the building may be delayed due to security checks and the requirement to be escorted to the meeting by a federal government employee. To request an escort to the meeting after entering the building, call Mario Lombre at (301) 443–3196. The meeting will be held at the Parklawn Building, Conference Room 10–65, 5600 Fishers Lane, Rockville, MD 20857. 2. (Audio Portion) Calling the conference phone number, 877–917– 4913, and providing the following information: Leaders Name: Dr. Vito Caserta Password: ACCV 3. (Visual Portion) Connecting to the ACCV Adobe Connect Pro Meeting using the following URL: https:// hrsa.connectsolutions.com/accv/ (copy and paste the link into your browser if it does not work directly, and enter as a guest). Participants should call and connect 15 minutes prior to the meeting in order for logistics to be set up. If you have never attended an Adobe Connect meeting, please test your connection using the following URL: https:// hrsa.connectsolutions.com/common/ help/en/support/meeting_test.htm and get a quick overview by following URL: https://www.adobe.com/go/connectpro_ overview. Call (301) 443–6634 or send VerDate Mar<15>2010 20:58 Feb 14, 2014 Jkt 232001 an email to aherzog@hrsa.gov if you are having trouble connecting to the meeting site. Agenda: The agenda items for the March meeting will include, but are not limited to: (1) Updates from the Division of Vaccine Injury Compensation (DVIC), Department of Justice, National Vaccine Program Office, Immunization Safety Office (Centers for Disease Control and Prevention), National Institute of Allergy and Infectious Diseases (National Institutes of Health) and Center for Biologics, and Evaluation and Research (Food and Drug Administration); (2) Report from the ACCV Process Workgroup; (3) Review of Vaccine Information Statements; and (4) Presentation on Pneumococcal Polysaccharide (Pneumovax 23) Vaccine Safety Review. A draft agenda and additional meeting materials will be posted on the ACCV Web site (https:// www.hrsa.gov/vaccinecompensation/ accv.htm) prior to the meeting. Agenda items are subject to change as priorities dictate. Public Comment: Persons interested in providing an oral presentation should submit a written request, along with a copy of their presentation to: Annie Herzog, DVIC, Healthcare Systems Bureau (HSB), Health Resources and Services Administration (HRSA), Room 11C–26, 5600 Fishers Lane, Rockville, MD 20857 or email: aherzog@hrsa.gov. Requests should contain the name, address, telephone number, email address, and any business or professional affiliation of the person desiring to make an oral presentation. Groups having similar interests are requested to combine their comments and present them through a single representative. The allocation of time may be adjusted to accommodate the level of expressed interest. DVIC will notify each presenter by email, mail, or telephone of their assigned presentation time. Persons who do not file an advance request for a presentation, but desire to make an oral statement, may announce it at the time of the public comment period. Public participation and ability to comment will be limited to space and time as it permits. FOR FURTHER INFORMATION CONTACT: Anyone requiring information regarding the ACCV should contact Annie Herzog, DVIC, HSB, HRSA, Room 11C–26, 5600 Fishers Lane, Rockville, MD 20857; telephone (301) 443–6634 or email: aherzog@hrsa.gov. PO 00000 Frm 00080 Fmt 4703 Sfmt 4703 Dated: February 11, 2014. Jackie Painter, Deputy Director, Division of Policy and Information Coordination. [FR Doc. 2014–03441 Filed 2–14–14; 8:45 am] BILLING CODE 4165–15–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Government-Owned Inventions; Availability for Licensing AGENCY: National Institutes of Health, HHS. ACTION: Notice. The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 209 and 37 CFR part 404 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing. FOR FURTHER INFORMATION CONTACT: Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852–3804; telephone: 301– 496–7057; fax: 301–402–0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications. SUMMARY: Multiple Antigenic Peptide Assays for Detection of HIV and SIV Type Retroviruses Description of Technology: CDC scientists have developed multiple antigenic peptide immunoassays for the detection of human immunodeficiency virus (HIV) and/or simian immunodeficiency virus (SIV). HIV can be subdivided into two major types, HIV–1 and HIV–2, both of which are believed to have originated as result of zoonotic transmission. Humans are increasingly exposed to many different SIVs by wild primates. For example, human exposure to SIVs frequently occurs as a consequence of the bush meat hunting and butchering trade in Africa. Human exposure to SIVs may lead, or may have already led, to transmission of SIVs with potential for new virus induced immunodeficiency epidemics. Unfortunately, new cases of E:\FR\FM\18FEN1.SGM 18FEN1

Agencies

[Federal Register Volume 79, Number 32 (Tuesday, February 18, 2014)]
[Notices]
[Pages 9235-9236]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-03441]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Health Resources and Services Administration


Advisory Commission on Childhood Vaccines; Notice of Meeting

    In accordance with section 10(a)(2) of the Federal Advisory 
Committee Act

[[Page 9236]]

(Public Law 92-463), notice is hereby given of the following meeting:
    Name: Advisory Commission on Childhood Vaccines (ACCV).
    Date and Time: March 6, 2014, 1:00 p.m. to 4:15 p.m. EDT; March 7, 
2014, 9:00 a.m. to 12:00 p.m. EDT.
    Place: Parklawn Building (and via audio conference call and Adobe 
Connect), Conference Room 10-65, 5600 Fishers Lane, Rockville, MD 
20857.
    The ACCV will meet on Thursday, March 6, 2014, 1:00 p.m. to 4:15 
p.m. EDT and Friday, March 7, 2014, 9:00 a.m. to 12:00 p.m. EDT. The 
public can join the meeting by:
    1. (In Person) Persons interested in attending the meeting [in 
person] are encouraged to submit a written notification to: Annie 
Herzog, DVIC, Healthcare Systems Bureau (HSB), Health Resources and 
Services Administration (HRSA), Room 11C-26, 5600 Fishers Lane, 
Rockville, Maryland 20857 or email: aherzog@hrsa.gov. Since this 
meeting is held in a federal government building, attendees will need 
to go through a security check to enter the building and participate in 
the meeting. This written notification is encouraged so that a list of 
attendees can be provided to expedite entry through security. Persons 
may attend in person without providing written notification, but their 
entry into the building may be delayed due to security checks and the 
requirement to be escorted to the meeting by a federal government 
employee. To request an escort to the meeting after entering the 
building, call Mario Lombre at (301) 443-3196. The meeting will be held 
at the Parklawn Building, Conference Room 10-65, 5600 Fishers Lane, 
Rockville, MD 20857.
    2. (Audio Portion) Calling the conference phone number, 877-917-
4913, and providing the following information:

Leaders Name: Dr. Vito Caserta
Password: ACCV

    3. (Visual Portion) Connecting to the ACCV Adobe Connect Pro 
Meeting using the following URL: https://hrsa.connectsolutions.com/accv/ (copy and paste the link into your browser if it does not work 
directly, and enter as a guest). Participants should call and connect 
15 minutes prior to the meeting in order for logistics to be set up. If 
you have never attended an Adobe Connect meeting, please test your 
connection using the following URL: https://hrsa.connectsolutions.com/common/help/en/support/meeting_test.htm and get a quick overview by 
following URL: https://www.adobe.com/go/connectpro_overview. Call (301) 
443-6634 or send an email to aherzog@hrsa.gov if you are having trouble 
connecting to the meeting site.
    Agenda: The agenda items for the March meeting will include, but 
are not limited to: (1) Updates from the Division of Vaccine Injury 
Compensation (DVIC), Department of Justice, National Vaccine Program 
Office, Immunization Safety Office (Centers for Disease Control and 
Prevention), National Institute of Allergy and Infectious Diseases 
(National Institutes of Health) and Center for Biologics, and 
Evaluation and Research (Food and Drug Administration); (2) Report from 
the ACCV Process Workgroup; (3) Review of Vaccine Information 
Statements; and (4) Presentation on Pneumococcal Polysaccharide 
(Pneumovax 23) Vaccine Safety Review. A draft agenda and additional 
meeting materials will be posted on the ACCV Web site (https://www.hrsa.gov/vaccinecompensation/accv.htm) prior to the meeting. Agenda 
items are subject to change as priorities dictate.
    Public Comment: Persons interested in providing an oral 
presentation should submit a written request, along with a copy of 
their presentation to: Annie Herzog, DVIC, Healthcare Systems Bureau 
(HSB), Health Resources and Services Administration (HRSA), Room 11C-
26, 5600 Fishers Lane, Rockville, MD 20857 or email: aherzog@hrsa.gov. 
Requests should contain the name, address, telephone number, email 
address, and any business or professional affiliation of the person 
desiring to make an oral presentation. Groups having similar interests 
are requested to combine their comments and present them through a 
single representative. The allocation of time may be adjusted to 
accommodate the level of expressed interest. DVIC will notify each 
presenter by email, mail, or telephone of their assigned presentation 
time. Persons who do not file an advance request for a presentation, 
but desire to make an oral statement, may announce it at the time of 
the public comment period. Public participation and ability to comment 
will be limited to space and time as it permits.

FOR FURTHER INFORMATION CONTACT: Anyone requiring information regarding 
the ACCV should contact Annie Herzog, DVIC, HSB, HRSA, Room 11C-26, 
5600 Fishers Lane, Rockville, MD 20857; telephone (301) 443-6634 or 
email: aherzog@hrsa.gov.

    Dated: February 11, 2014.
Jackie Painter,
Deputy Director, Division of Policy and Information Coordination.
[FR Doc. 2014-03441 Filed 2-14-14; 8:45 am]
BILLING CODE 4165-15-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.